Penumbra is drawing attention after Novant Health reported successful use of its newly cleared THUNDERBOLT computer assisted vacuum thrombectomy system at a North Carolina comprehensive stroke center. The stock trades at $318.73, about 13% below the average analyst price target, with a popular narrative suggesting a fair value of roughly $363 and a 12.3% undervaluation. However, a Simply Wall St DCF model points to a fair value of $216.68, implying the stock is trading well above its estimated future cash flow value. The upcoming STORM PE randomized trial is expected to provide Level 1 evidence comparing Penumbra's thrombectomy technology to standard anticoagulation for pulmonary embolism, which could significantly expand guideline adoption and procedure volumes. Investors are weighing these conflicting valuation signals against risks including reliance on key franchises and rising competitive and regulatory pressure.
Penumbra IncSuccessful use of newly cleared THUNDERBOLT system and upcoming STORM PE trial expected to expand adoption.